Xencor selects proposed Phase 3 dose after positive XmAb819 kidney cancer data

Xencor reported updated Phase 1 results for XmAb819 at the ESMO Congress on October 25, 2026. At the selected 400 mcg/kg intravenous dose, 5 of 11 evaluable patients had confirmed partial responses, producing a 45.5% confirmed objective response rate, while estimated six-month progression-free survival was 82%. Xencor plans to discuss a possible accelerated-approval route with the FDA in the first half of 2027 and develop a global randomized study against tivozanib for previously treated advanced clear cell renal cell carcinoma.

The 400 mcg/kg selection moves XmAb819 toward registration-enabling development, although the efficacy signal comes from a small Phase 1 cohort and still requires regulatory discussions and larger trials. The proposed trial and FDA meeting create future development milestones for Xencor, but neither guarantees approval.

  • 1Xencor chose 400 mcg/kg intravenously as the proposed recommended Phase 3 dose for XmAb819.
  • 2The 400 mcg/kg cohort had a 45.5% confirmed objective response rate among 11 evaluable patients, with estimated six-month progression-free survival of 82%.
  • 3Xencor plans a first-half 2027 meeting with the U.S. Food and Drug Administration to discuss potential accelerated approval in selected advanced kidney-cancer populations.
  • 4The planned randomized study will test XmAb819 alone against tivozanib in patients whose disease progressed after earlier immune-checkpoint and VEGFR-targeted treatment.
  • 5Xencor expects to begin a registration-enabling study in 2027 and says its cash runway extends into 2029.
  • The response rate is based on only 11 evaluable patients, so durability and results in larger randomized studies remain unknown.
  • The potential accelerated-approval route, trial timing and eventual regulatory outcome remain subject to FDA discussions and future data.

Sources